1
0
0
(1 - 28 von 33
)
Effects of empagliflozin on the urinary albumin-to- ...The Lancet
www.thelancet.com
von DZI Cherney · · Zitiert von: 407 — Audrey Koitka-Weber, PhD. Audrey Koitka-Weber. Affiliations. Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany. Search for ... von DZI Cherney · · Zitiert von: 407 — Audrey Koitka-Weber, PhD. Audrey Koitka-Weber. Affiliations. Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany. Search for ...
Nephrotic-range proteinuria in type 2 diabetes: Effects of ...The Lancet
www.thelancet.com
von P Ruggenenti · · Zitiert von: 8 — ... Audrey Koitka-Weber,c,k,1 and Christoph Wannerc1. aDepartment of Renal Medicine, Clinical Research Center for Rare Diseases "Aldo and Cele ... von P Ruggenenti · · Zitiert von: 8 — ... Audrey Koitka-Weber,c,k,1 and Christoph Wannerc1. aDepartment of Renal Medicine, Clinical Research Center for Rare Diseases "Aldo and Cele ...
An Analysis From the EMPA-REG OUTCOME TrialAmerican Journal of Kidney Diseases
www.ajkd.org
von ME Cooper · · Zitiert von: 41 — Audrey Koitka-Weber, PhD. Audrey Koitka-Weber. Affiliations. Department of Diabetes, Central Clinical School, Monash University, Melbourne ... von ME Cooper · · Zitiert von: 41 — Audrey Koitka-Weber, PhD. Audrey Koitka-Weber. Affiliations. Department of Diabetes, Central Clinical School, Monash University, Melbourne ...
Effects of empagliflozin on the urinary albumin-to- ...boehringerone.com
www.boehringerone.com
von DZI Cherney · · Zitiert von: 407 — ... Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Summary. Background In a pooled analysis of short-term ... von DZI Cherney · · Zitiert von: 407 — ... Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Summary. Background In a pooled analysis of short-term ...
Empagliflozin and incidence of events consistent with ...UCL Discovery
discovery.ucl.ac.uk
von R Agarwal · · Zitiert von: 1 — The authors thank Audrey Koitka-Weber and Maximilian von. Eynatten, who were employees of Boehringer Ingelheim at the time the research was carried out, for ... von R Agarwal · · Zitiert von: 1 — The authors thank Audrey Koitka-Weber and Maximilian von. Eynatten, who were employees of Boehringer Ingelheim at the time the research was carried out, for ...
Linagliptin and its effects on hyperglycaemia and albuminuria ...Helsinki.fi
researchportal.helsinki.fi
von RCS MD13 · · Zitiert von: 157 — Thomas Meinicke MD16 | Audrey Koitka-Weber PhD16 | Sandra Thiemann PhD17 |. Maximilian von Eynatten MD17. 1Folkhälsan Institute of Genetics, Folkhälsan. von RCS MD13 · · Zitiert von: 157 — Thomas Meinicke MD16 | Audrey Koitka-Weber PhD16 | Sandra Thiemann PhD17 |. Maximilian von Eynatten MD17. 1Folkhälsan Institute of Genetics, Folkhälsan.
Characterization and implications of the initial estimated ...ScienceDirect.com
www.sciencedirect.com
von BJ Kraus · · Zitiert von: 156 — , Bernard Zinman 14 , Silvio E. Inzucchi 15 , Christoph Wanner 2 , Audrey Koitka-Weber Show more. Add to Mendeley. Share. Cite. https://doi.org von BJ Kraus · · Zitiert von: 156 — , Bernard Zinman 14 , Silvio E. Inzucchi 15 , Christoph Wanner 2 , Audrey Koitka-Weber Show more. Add to Mendeley. Share. Cite. https://doi.org/ ...
Insights From The Emperial TrialsScienceDirect.com
www.sciencedirect.com
von SD Anker · · Zitiert von: 1 — , Ivana Ritter 4 , Matias Nordaby 4 , Audrey Koitka-Weber 3 4 , Martina Brueckmann 4 , Waheed Jamal 4 , JoAnn Lindenfeld 7 , William T. Abraham von SD Anker · · Zitiert von: 1 — , Ivana Ritter 4 , Matias Nordaby 4 , Audrey Koitka-Weber 3 4 , Martina Brueckmann 4 , Waheed Jamal 4 , JoAnn Lindenfeld 7 , William T. Abraham 1 8.
Cost-Effectiveness of Empagliflozin in Patients With Diabetic ...
www.sciencedirect.com
von OS Reifsnider · · Zitiert von: 3 — Authors' Full Names and Academic Degrees. Odette S. Reifsnider, PhD, Anuraag R. Kansal, PhD, Christoph Wanner, MD, Egon Pfarr, MS, Audrey Koitka-Weber ... › pii
A Slope Analysis from the EMPA-REG OUTCOME Trial. ...Europe PMC
europepmc.org
von C Wanner · · Zitiert von: 199 — ... Audrey Koitka-Weber,1,5,6 Michaela Mattheus,5 Stefan Hantel,7 Hans-Juergen Woerle,8 Uli C. Broedl,5 Maximilian von Eynatten,5 Per-Henrik Groop,6,9,10,11 and ... von C Wanner · · Zitiert von: 199 — ... Audrey Koitka-Weber,1,5,6 Michaela Mattheus,5 Stefan Hantel,7 Hans-Juergen Woerle,8 Uli C. Broedl,5 Maximilian von Eynatten,5 Per-Henrik Groop,6,9,10,11 and ...
An Exploratory Analysis From the EMPA-REG OUTCOME ...Kidney Medicine
www.kidneymedicinejournal.org
von S Hadjadj · · Zitiert von: 1 — The authors also thank Audrey Koitka-Weber and Max von Eynatten, who were employees of Boehringer Ingelheim at the time of the research, for ... von S Hadjadj · · Zitiert von: 1 — The authors also thank Audrey Koitka-Weber and Max von Eynatten, who were employees of Boehringer Ingelheim at the time of the research, for ...
Characterization and implications of the initial estimated ...CiNii
cir.nii.ac.jp
von BJ Kraus · · Zitiert von: 154 — Audrey Koitka-Weber. 収録刊行物. Kidney International. Kidney International 99 (3)Elsevier BV. 被引用文献 (1)*注記. 読み込み中... もっと見る ... von BJ Kraus · · Zitiert von: 154 — Audrey Koitka-Weber. 収録刊行物. Kidney International. Kidney International 99 (3)Elsevier BV. 被引用文献 (1)*注記. 読み込み中... もっと見る ...
Analysis from the EMPA-REG OUTCOME® trial indicates ...CiNii
cir.nii.ac.jp
von GJ Mayer · · Zitiert von: 92 — Audrey Koitka-Weber · Stefan Hantel · Maximilian von Eynatten · Bernard Zinman · David Z.I. Cherney. 収録刊行物. Kidney International. Kidney International 96 ( ...
Empagliflozin Improves Kidney Outcomes in Patients With ...Internet Archive Scholar
scholar.archive.org
von J Butler · · Zitiert von: 57 — Audrey Koitka-Weber,. PhD. Maximilian von Eynatten,. MD. Isabella Zwiener, PhD. Jyothis George, MBBS,. PhD, FRCP. Martina Brueckmann, MD. Alfred K. Cheung, MD. von J Butler · · Zitiert von: 57 — Audrey Koitka-Weber,. PhD. Maximilian von Eynatten,. MD. Isabella Zwiener, PhD. Jyothis George, MBBS,. PhD, FRCP. Martina Brueckmann, MD. Alfred K. Cheung, MD.
Empagliflozin Improves Kidney Outcomes in Patients With ...American Heart Association Journals
www.ahajournals.org
von J Butler · · Zitiert von: 57 — ... Audrey Koitka-Weber, PhD, Maximilian von Eynatten, MD, Isabella Zwiener, PhD, Jyothis George, MBBS, PhD, FRCP, Martina Brueckmann, MD ... von J Butler · · Zitiert von: 57 — ... Audrey Koitka-Weber, PhD, Maximilian von Eynatten, MD, Isabella Zwiener, PhD, Jyothis George, MBBS, PhD, FRCP, Martina Brueckmann, MD ...
Empagliflozin and kidney outcomes in Asian patients with ...X-MOL
www.x-mol.com
von T Kadowaki · · Zitiert von: 71 — Audrey Koitka-Weber,. Audrey Koitka-Weber. Boehringer Ingelheim International GmbH, Ingelheim, Germany. Department of Medicine, Würzburg ...
Findings Based on the EMPA-REG OUTCOME TrialNational Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von OS Reifsnider · · Zitiert von: 25 — ... Audrey Koitka-Weber , Sarah B Brand , Matthew Stargardter , Cheng Wang , Effie Kuti , Anastasia Ustyugova. Affiliations. 1 Evidera, Bethesda ...
Glucose Control and the Effect of Empagliflozin on Kidney ...Monash University
research.monash.edu
von ME Cooper · · Zitiert von: 41 — ... Eynatten, Christoph Wanner, Audrey Koitka-Weber. Diabetes. Research output: Contribution to journal › Letter › Other › peer-review. 38 Citations (Scopus). von ME Cooper · · Zitiert von: 41 — ... Eynatten, Christoph Wanner, Audrey Koitka-Weber. Diabetes. Research output: Contribution to journal › Letter › Other › peer-review. 38 Citations (Scopus).
Glucose Control and the Effect of Empagliflozin on Kidney ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von ME Cooper · · Zitiert von: 41 — ... Audrey Koitka-Weber. Affiliations. 1 Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia. Electronic address: mark ... von ME Cooper · · Zitiert von: 41 — ... Audrey Koitka-Weber. Affiliations. 1 Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia. Electronic address: mark ...
Insights from the EMPA-REG OUTCOME trialNational Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von C Wanner · · Zitiert von: 32 — Authors. Christoph Wanner , Silvio E Inzucchi , Bernard Zinman , Audrey Koitka-Weber , Michaela Mattheus , Jyothis T George , Maximilian von ...
Renal hemodynamic effects of sodium-glucose ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von EJM van Bommel · · Zitiert von: 46 — ... Audrey Koitka-Weber , Jaap A Joles , David Z I Cherney , Daniël H van Raalte. Affiliations. 1 Diabetes Center, Department of Internal Medicine ... von EJM van Bommel · · Zitiert von: 46 — ... Audrey Koitka-Weber , Jaap A Joles , David Z I Cherney , Daniël H van Raalte. Affiliations. 1 Diabetes Center, Department of Internal Medicine ...
so019 effects of empagliflozin on cardiovascular outcomes ...Oxford Academic
academic.oup.com
von V Perkovic · · Zitiert von: 3 — Audrey Koitka-Weber ,. Audrey Koitka-Weber. 3Medical Affairs Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany. Search for other works ... von V Perkovic · · Zitiert von: 3 — Audrey Koitka-Weber ,. Audrey Koitka-Weber. 3Medical Affairs Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany. Search for other works ...
sp259 effects of empagliflozin on renal outcomes across kdigo ...Oxford Academic
academic.oup.com
von T Kuhlmann · · Zitiert von: 909 — Audrey Koitka-Weber ,. Audrey Koitka-Weber. 2Medical Affairs Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany. Search for other works ... von T Kuhlmann · · Zitiert von: 909 — Audrey Koitka-Weber ,. Audrey Koitka-Weber. 2Medical Affairs Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany. Search for other works ...
Cardio/Kidney Composite End PointsAmerican Heart Association Journals
www.ahajournals.org
von JP Ferreira · · Zitiert von: 14 — Fitchett, MD; Audrey Koitka- Weber, PhD; Jyothis T. George, MBBS, PhD;. Anne Pernille Ofstad , MD; Christoph Wanner, MD; Faiez Zannad , MD, PhD. BACKGROUND ... von JP Ferreira · · Zitiert von: 14 — Fitchett, MD; Audrey Koitka- Weber, PhD; Jyothis T. George, MBBS, PhD;. Anne Pernille Ofstad , MD; Christoph Wanner, MD; Faiez Zannad , MD, PhD. BACKGROUND ...
Characterization and implications of the initialKidney International
www.kidney-international.org
von BJ Kraus · · Zitiert von: 152 — Inzucchi15, Christoph Wanner2 and Audrey Koitka-Weber1,2,16. 1Medical Affairs, Boehringer Ingelheim International GmbH, Ingelheim, Germany ... von BJ Kraus · · Zitiert von: 152 — Inzucchi15, Christoph Wanner2 and Audrey Koitka-Weber1,2,16. 1Medical Affairs, Boehringer Ingelheim International GmbH, Ingelheim, Germany ...
Cost of treating diabetic kidney disease Dasgupta I - Indian J ...
www.indianjnephrol.org
von I Dasgupta · · Zitiert von: 7 — Odette S. Reifsnider, Anuraag R. Kansal, Christoph Wanner, Egon Pfarr, Audrey Koitka-Weber, Sarah B. Brand, Matthew Stargardter, Cheng Wang, ... › a...
Cost-Effectiveness of Empagliflozin in Patients With Diabetic ...
www.ajkd.org
von OS Reifsnider · · Zitiert von: 3 — Odette S. Reifsnider, Anuraag R. Kansal, Christoph Wanner, Egon Pfarr, Audrey Koitka-Weber, Sarah B. Brand,. Matthew Stargardter, Cheng Wang PhD, FRACP, Silvio E. Inzucchi, MD, Bernard Zinman, MD, Stefan Hantel, PhD, Maximilian von Eynatten, MD, Christoph Wanner, MD, Audrey Koitka-Weber, PhD. › article › pdf › article › ppt
International consensus definitions of clinical trial outcomes ...CiNii Research
cir.nii.ac.jp
von A Levin · · Zitiert von: 52 — Audrey Koitka-Weber · Matthias Kretzler · Robert Lawatscheck · Adrian Liew · Louise Moist · Saraladevi Naicker · Reiko Nakashima.
Alle Infos zum Namen "Audrey Koitka-Weber"
sortiert nach Relevanz / Datum